Presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Scientific Meeting held February 19-21, 2020 in Washington, DC

While several instruments assessing clinical symptoms of MS exist, few incorporate the participant’s experience of such symptoms.Consistent with recent expressed preferences from regulatory agencies and market access experts to assess how patients “feel and function,” the Multiple Sclerosis Individualized Outcome Assessment (MSIOA) is a structured clinical interview developed to evaluate and establish a profile of clinical symptoms for individuals with MS, to identify symptoms that are most distressing, and to evaluate change over time. This presentation describes baseline data on the MSIOA from two ongoing clinical trials in MS.

Download Poster